Selected References:

• Chu S, et al. 2015. Periconceptional and Gestational Exposure to Antibiotics and Childhood Asthma. PLoS One 10(10):e0140443
• Crider KS, et al. 2009. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med. 163(11):978-985.
• Czeizel AE, et al. 1999. A population-based case-control teratological study of three parenteral penicillins G. Congenital Anomalies 39:117-126.
• Dencker BB, et al. 2002. Birth outcome of 1886 pregnancies after exposure to phenoxymethylpenicillin in utero. Clin Microbiol Infect 8:196-201.
• Gallager, JS. 1988. Anaphylaxis in pregnancy. Obstet Gynecol 71:491-493.
• Greene H, et al. 1946. Excretion of penicillin in human milk following parturition. Am J Obstet Gynecol 51:732-733.
• Heinonen OP, et al. 1977. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group: 299-313, 435.
• Jepsen P, et al. 2003. A population-based study of maternal use of amoxicillin and pregnancy outcome in Denmark. Br J Clin Pharmacol 55(2):216-221.
• Kosim H. 1959. Intrauterine fetal death as a result of anaphylactic reaction to penicillin in a pregnant woman. Dapim Refuiim 18:136-137.
• Meeraus WH, et al. 2015. Association between antibiotic prescribing in pregnancy and cerebral palsy or epilepsy in children born at term: a cohort study using the health improvement network. PLoS One 10(3): e0122034.
• Nahum GG, et al. 2006. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol 107(5):1120-38.
• Njotto LL, et al. 2023. Maternal and early-life exposure to antibiotics and the risk of autism and attention-deficit hyperactivity disorder in childhood: a Swedish population-based cohort study. Drug Saf. 46(5):467-478.
• Ortqvist AK, et al. 2014. Antibiotics in fetal and early life and subsequent childhood asthma: nationwide population based study with sibling analysis. BMJ. 349:g6979.
• Ravid R & Toaff R. 1972. On the possible teratogenicity of antibiotic drugs administered during pregnancy – a prospective study. Drugs and Fetal Development: 505-510.
• Simons & Schatz. 2012. Anaphylaxis during pregnancy. J Allergy Clin Immunol 130(3): 597-606.

Selected References

• Asghar, et al.2024. LTRA use in pregnancy: a systematic review on their safety and association with congenital anomalies’. Journal of Regenerative Medicine, 13(2):1-8.
• Committee on Drugs. American Academy of Pediatrics. 2001. The transfer of drugs and other chemicals into human milk. Pediatrics, 108:776-789.
• Cossette B, et al. 2014. Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. Annals of Allergy, Asthma & Immunology, 112(5):459–464.
• Eltonsy S, et al. 2011. Beta2-agonists use during pregnancy and the risk of congenital malformations. Birth Defects Research Part A: Clinical and Molecular Teratology, 91(11):937–947.
• Gregersen TL and Ulrik CS. 2013. Safety of bronchodilators and corticosteroids for asthma during pregnancy: what we know and what we need to do better. J Asthma Allergy, 6:117–125.
• Lim A, et al. 2013. Asthma drugs in pregnancy and lactation. Australian Prescriber, 36(5):150–153.
• Lim A, et al. 2011. Systematic review of the safety of regular preventive asthma medications during pregnancy, Ann Pharmacother, 45(7-8):931-945.
• Namazy J, and Schatz M. 2018. Management of asthma during pregnancy: optimizing outcomes and minimizing risk. Seminars in Respiratory and Critical Care Medicine, 39(01): 029–035.
• National Asthma Education and Prevention Program. Working Group. 2004. Report on managing asthma during pregnancy: Recommendations for pharmacologic treatment. Update 2004. NIH publication NO.05-5236. Bethesda, MD: US Department of Health and Human Services; National Institutes of Health; National Heart, Lung and Blood Institute.
• Tamasi L, et al. 2005. The management of bronchial asthma during pregnancy – Hungarian experiences. Orv Hetil. 146(45):2035-2039.
• Wilton LV and Shakir SA. 2002. A postmarketing surveillance study of formoterol (Foradil). Its use in general practice in England. Drug Saf 25:213-223

Selected References:

• Agache I, et al. 2010. Risk factors and asthma phenotypes in children and adults with seasonal allergic rhinitis. Phys Sportsmed 38(4):81-86.
• Cao S, et al. 2020. Changes in children’s asthma prevalence over two decades in Lanzhou: effects of socioeconomic, parental and household factors. J Thorac Dis 12(10):6365-6378.
• Centers for Disease Control and Prevention. 2020. General Information about Mold. Available from URL: https://www.cdc.gov/mold-health/about/index.html
• Centers for Disease Control and Prevention. 2004. Investigation of acute idiopathic pulmonary hemorrhage among infants – Massachusetts, December 2002-June 2003. MMWR 53:817-820.
• Centers for Disease Control and Prevention. 2020. Natural Disasters and Severe Weather. Mold after a Disaster. Available from URL: https://www.cdc.gov/disasters/mold/.
• Centers for Disease Control and Prevention. 2000. Update: pulmonary hermorrhage/hemosiderosis among infants – Cleveland, Ohio, 1993-1996. MMWR 49:180-184.
• DiPaolo JA, et al. 1967. Teratogenic response by hamsters, rats and mice to aflatoxin B1. Nature 215:638-9.
• Etzel RA, et al. 1998. Acute pulmonary hemorrhage in infants associated with exposure to Stachybotrys atra and other fungi. Arch Pediatr Adolesc Med 152:757-762.
• Gallant MJ, et al. 2020. Prenatal and early-life exposure to indoor air-polluting factors and allergic sensitization at 2 years of age. Ann Allergy Asthma Immunol 124(3):283-287.
• Hayes AW, et al. 1974. Teratogenic effects of ochratoxin A in mice. Teratology 9:93-7.
• Korpinen E. 1974. Studies on Stachybotrys alternans: effect of low doses of stachybotrys toxins on pregnancy of mice. Acta Path Microbiol Scand 82:457-464.
• Lee E, et al. 2020. Prenatal mold exposure is associated with development of atopic dermatitis in infants through allergic inflammation. J Pediatr (Rio J) 96:125–31.
• Loth EA, et al. 2015. Experimental Paracoccidioiomycosis in pregnant rats. Rev Inst Med Trop San Paulo 57(6): 515-518.
• Magoha H, et al. 2014. Association between aflatoxin M1 exposure through breast milk and growth impairment in infants from Northern Tanzania. World Mycotoxin J 7(3): 277-284.
• Magoha H, et al. 2014. Fumonisin B1 contamination in breast milk and its exposure in infants under 6 months of age in Rombo, Northern Tanzania. Food Chem Toxicol 74:112-116.
• Martyny JW, et al. 2005. Aerosolized sodium hypochlorite inhibits viability and allergenicity of mold on building materials. J Allergy Clin Immunol 116:630-635.
• Reddy CS, et al. 1981. Teratogenicity of secalonic acid D in mice. J Toxicol Environ Health 7:445-55.
• Strina A, et al. 2014. Risk factors for no-atopic asthma/wheeze in children and adolescents: a systematic review. Emerg Themes Epidemiol 11:5.
• US Environmental Protection Agency (EPA). 2024. Mold and Health. Available at URL: https://www.epa.gov/mold/mold-and-health
• US Environmental Protection Agency (EPA). 2018. Mold and Your Home. Available at URL: https://www.epa.gov/mold/mold-and-your-home.

Selected References:

• Akbari M, et al. 2013. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis, 19(1):15-22.
• Alami Z, et al. 2018. Pregnancy outcome following in utero exposure to azathioprine: a French comparative observational study. Therapie, 73(3):199-207.
• Alshwairikh LA, Zeneb B. 2022. A 25-year-old Saudi woman with a 2-year history of antisynthetase syndrome with interstitial lung disease who commenced azathioprine treatment in the third trimester of pregnancy and had a successful birth at term. Am J Case Rep, 7:23:e936833.
• Balevic S, et al. 2024. Azathioprine metabolite levels and outcomes during pregnancies with rheumatic disease. Lupus Sci Med, 11(1):e0011036.
• Casanova MJ, et al. 2013. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol, 108(3):433-440.
• Christensen LA, et al. 2008. Azathioprine treatment during lactation. Aliment Pharmacol Ther, 28(10):1209-1213.
• Davison JM et al. 1985. Maternal azathioprine therapy and depressed haematopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol, 92:233-239.
• de Meij TG, et al. 2013. Dutch Initiative on crohn and colitis. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment Pharmacol Ther, 38(1):38-43.
• Dejaco C, et al. 2001. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology, 121:1048-53.
• Francella A, et al. 2003. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology, 124(1):9-17.
• Friedman S, et al. 2017. Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring: a nationwide cohort study. Reproductive Toxicology, 73:196-200.
• Götestam Skorpen C, et al. 2016. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis, 75(5):795-810.
• Goldstein LH, et al. 2007. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol, 79(10):696-701.
• Hoeltzenbein M, et al. 2012. Pregnancy outcome after paternal exposure to azathioprine/6-mercaptopurine. Reprod Toxicol, 34(3):364-369.
• Ikram N, at al. 2021. Breastfeeding in women with rheumatic diseases. Lupus Sci Med, 8(1):e000491.
• Khedr L, Ekram M. 2024. Eur J Case Rep Intern Med, 11(4):004385.
• Kinnucan J, Kane S. 2021. Editorial: thiopurines but not anti-TNF monotherapy are linked to worse pregnancy outcomes in a large population-based study. Aliment Pharmacol Ther, 54(3):343-344.
• Langagergaard V, et al. 2007. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther, 25(1):73-81.
• Matalon ST, et al. 2004. Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol, 18(2):219-230.
• Matarazzo L, et al. 2021. Pregnancy outcome in women with childhood onset autoimmune hepatitis and autoimmune sclerosing cholangitis on long-term immunosuppressive treatment. Eur J Obstet Gynecol Reprod Biol, 268:7-11.
• Moretti ME et al. 2006. Breast-feeding during maternal use of azathioprine. Ann Pharmacother, 40(12):2269-2272.
• Motta M, et al. 2007. Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents. Am J Perinatol, 24(8):441-447.
• Myer A, et al. 2021. Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018. Aliment Pharmacol Ther, 54(3):302-311.
• Nørgård B, et al. 2004. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther, 19(6):679-685.
• Reynolds JA, et al. 2023. Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology (Oxford), 62(3):1124-1135.
• Skejo C, et al. 2024. Early onset sepsis and lobar pneumonia in a newborn exposed in utero to Ustekinumab and azathioprine. Inflamm Bowel Dis, 30(2):314-315.
• Wolf MF, et al. 2023. Azathioprine and 6-mercaptopurine-induced intrahepatic cholestasis of pregnancy: case report and review of literature: Taiwan J Obstet Gynecol, 63(5):761-764.

Selected References:

• Adank MC, et al. 2019. Is maternal lipid profile in early pregnancy associated with pregnancy complications and blood pressure in pregnancy and long term postpartum?.Obstet Gynecol. 221(2): 150-e1.
• Arias A, et al. 2022. Implications of High-Density Cholesterol Metabolism for Oocyte Biology and Female Fertility. Frontiers in cell and developmental biology, vol. 10, 941539.
• Berge LN, et al. 1996. Pregnancy related changes in some cardiovascular risk factors. Acta Obstet. Gynecol. Scand. 75 pp. 439–442.
• Brizzi P, et al. 1999. Lipoprotein metabolism during normal pregnancy. Obstet Gynecol. 181 (2): 430-34.
• Christensen S, et al. 2023. Maternal inflammatory, lipid and metabolic markers and associations with birth and breastfeeding outcomes. Frontiers in nutrition, v10, 1223753.
• Christopher BA, et al. 2019. Evaluation and management of lipid disorders: summary. Clinical Updates in Women’s Health Care. American College of Obstetricians and Gynecologists. Obstet Gynecol. 133:609.
• Cristodoro M, et al. 2024. Dietary Patterns and Fertility. Biology,13(2),131.
• France M, et al. 2016. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis. 255:128-139.
• Graham DF, et al. 2021. Management of familial hypercholesterolemia in pregnancy. Curr Opin Lipidol. 32(6):370-377. PMID: 34619689 DOI: 10.1097/MOL.0000000000000790
• Goharkhay N, et al. 2008. Maternal hypercholesterolemia leads to activation of endogenous cholesterol synthesis in the offspring. Amer J Obstet Gynecol. 199(3): 273-e1.
• Goldberg AC et al. 2011. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S1-8.
• Gootjes D, et al. 2022. Maternal lipid profile in pregnancy and embryonic size: a population-based prospective cohort study. BMC pregnancy and childbirth; 22(1):333.
• Jiang S et al. 2017. Maternal dyslipidemia during pregnancy may increase the risk of preterm birth: A meta-analysis. Taiwan J Obstet Gynecol. 56(1):9-15.
• Kaneko K, et al. 2022. High Maternal Total Cholesterol Is Associated With No-Catch-up Growth in Full-Term SGA Infants: The Japan Environment and Children’s Study. Frontiers in endocrinology; vol. 13, 939366.
• Klevmoen M, et al. 2021. Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia. Atherosclerosis. 335:8-15. PMID: 34520888 DOI: 10.1016/j.atherosclerosis.2021.09.003
• Liberis A, et al. 2021. Lipid Disorders in Pregnancy. Curr Pharm Des. 27(36):3804-3807. PMID: 33882801 DOI: 10.2174/1381612827666210421103245
• Mauri M, et al. 2021. Dyslipemias and pregnancy, an update. Clin Investig Arterioscler. 33(1):41-52. PMID: 33309071 DOI: 10.1016/j.arteri.2020.10.002
• Moayeri M, et al. 2017. Maternal lipid profile and the relation with spontaneous preterm delivery: a systematic review. Arch Gynecol Obstet. 295(2):313-323.
• Mulder J, et al. 2024. Lipid metabolism during pregnancy: consequences for mother and child. Current opinion in lipidology; 35(3): 133-140.
• Napoli C, et al. 1999. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet. 354(9186): 1234-41.
• Nasioudis D, et al. 2018. Dyslipidemia in pregnancy and maternal-fetal outcome. Minerva ginecologica. 71(2):155-62.
• Ogura et al. 2016. Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion. Atherosclerosis. 254:179-183.
• Omolaoye T, et al. 2022. Statins and Male Fertility: Is There a Cause for Concern?. Toxics; 10(10):627.
• Pugh et al. 2017. Preconception maternal lipoprotein levels in relation to fecundability. Hum Reprod.15:1-9.
• Pushpendra A, et al. 2015. Hyper-lipidemia and male fertility: a critical review of literature. Andrology. 4(2).
• Schisterman EF, et al. 2014. Lipid concentrations and couple fecundity: the LIFE study. J Clin Endocrinol Metab. 99(8):2786-94.
• Schisterman EF, et al. 2014. Lipid concentrations and semen quality: the LIFE study. Andrology. 2(3):408-15.
• Sharami SH, 2019. The relationship of hyperlipidemia with maternal and neonatal outcomes in pregnancy: A cross-sectional study. International Journal of Reproductive BioMedicine. 17(10): 739.
• Smith CJ, et al. 2018. Maternal dyslipidemia and risk for preterm birth. PloS one. 13(12): e0209579.
• Toleikyte I, et al. 2011. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation. 124(15):1606-14.
• Varnier NA, et al. 2015. Coronary artery disease secondary to familial hypercholesterolaemia: An infrequent cause of increasingly common pregnancy co-morbidity. Obstet Med.8(3):152-4.
• Vrijkotte TG, et al. 2012. Maternal lipid profile during early pregnancy and pregnancy complications and outcomes: the ABCD study. The Journal of Clinical Endocrinology & Metabolism. 97(11): 3917-25.
• Wang C, et al. 2016. The associations between early pregnancy lipid profiles and pregnancy outcomes. J Perinatol.
• Whitfield M, et al. 2015. Posttesticular sperm maturation, infertility, and hypercholesterolemia. Asian J Androl. 17(5):742-8.
• Wild R, et al. 2015. Dyslipidemia in pregnancy. Cardiology clinics. 33(2): 209-15.
• Wojcik-Baszko D, et al. 2018. Role of dyslipidemia in preeclampsia—A review of lipidomic analysis of blood, placenta, syncytiotrophoblast microvesicles and umbilical cord artery from women with preeclampsia. Prostaglandins & Other Lipid Mediators. 139: 19-23.